Related Experiment Videos
Giving AXL the axe: targeting AXL in human malignancy
Carl M Gay1, Kavitha Balaji1, Lauren Averett Byers1
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
British Journal of Cancer
|January 11, 2017
Summary
The receptor tyrosine kinase AXL is overexpressed in many cancers, driving tumor growth and immune evasion. Targeting AXL offers a promising therapeutic strategy for various malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The receptor tyrosine kinase AXL plays a role in cell proliferation, survival, and immune response.
- AXL is overexpressed in numerous hematologic and solid tumors, including leukemia, lung, gastric, colorectal, breast, and prostate cancers.
Purpose of the Study:
- To review the structure, regulation, and function of AXL.
- To explore the role of AXL in the tumor microenvironment.
- To discuss the development of AXL as a therapeutic target for cancer treatment.
Main Methods:
- Literature review of AXL's role in cancer.
- Analysis of AXL's involvement in tumor progression and immune response.
- Overview of current AXL inhibitor development.
Main Results:
- AXL overexpression promotes epithelial-to-mesenchymal transition, angiogenesis, and chemoresistance.
- AXL contributes to decreased anti-tumor immune response.
- Several AXL inhibitors are in preclinical and clinical development.
Conclusions:
- AXL is a significant factor in cancer progression and a potential prognostic biomarker.
- Targeting AXL presents a promising therapeutic avenue for various cancers.
- Further research into AXL's role and inhibitor development is ongoing.